Affordable Access

deepdyve-link
Publisher Website

Hematopoietic stem cell transplantation in pediatric patients with thalassemia and sickle cell disease: An experience of the Spanish Working Group for Bone Marrow Transplantation in Children (GETMON).

Authors
  • Alonso, Laura1
  • González-Vicent, Marta2
  • Belendez, Cristina3
  • Badell, Isabel4
  • Sastre, Ana5
  • Rodríguez-Villa, Antonia6
  • Bermúdez-Cortés, Mar7
  • Hladun, Raquel8
  • Díaz de Heredia, Cristina8
  • 1 Unidad Pediátrica de Trasplante Hematopoyético, Hospital Universitario Vall d'Hebron, Barcelona, España. Electronic address: [email protected]
  • 2 Unidad Pediátrica de Trasplante Hematopoyético, Hospital Niño Jesús, Madrid, España.
  • 3 Unidad Pediátrica de Trasplante Hematopoyético, Hospital Universitario Gregorio Marañón, Madrid, España.
  • 4 Unidad Pediátrica de Trasplante Hematopoyético, Hospital de la Santa Creu i Sant Pau, Universidad Autónoma, Barcelona, España.
  • 5 Unidad Pediátrica de Trasplante Hematopoyético, Hospital La Paz, Madrid, España.
  • 6 Unidad Pediátrica de Trasplante Hematopoyético, Hospital Universitario Reina Sofía, Córdoba, España.
  • 7 Unidad Pediátrica de Trasplante Hematopoyético, Hospital Universitario Virgen de la Arrixaca, Murcia, España.
  • 8 Unidad Pediátrica de Trasplante Hematopoyético, Hospital Universitario Vall d'Hebron, Barcelona, España.
Type
Published Article
Journal
Medicina Clínica
Publisher
Elsevier
Publication Date
Feb 15, 2019
Volume
152
Issue
4
Pages
135–140
Identifiers
DOI: 10.1016/j.medcli.2018.05.013
PMID: 30001893
Source
Medline
Keywords
Language
Spanish
License
Unknown

Abstract

A recently occurring increase of the prevalence of haemoglobinopathies, β-thalassaemia major (TM) and sickle cell disease (SCD) over the last two decades in our country has generated new needs in terms of medical resources for both prevention and treatment of these patients. Allogeneic haematopoietic stem cell transplant (allo-HSCT) is a curative treatment available for patients who have severe haemoglobinopathies. The main objective of this study was to evaluate the results of allo-HSCT in paediatric patients with TM or SCD performed in paediatric hematopoietic transplant units within the Spanish Group of Bone Marrow Transplantation in Children (GETMON). Retrospective review of patients undergoing HSCT in the GETMON units until 2015. A total of 65 patients were analysed (43 patients were affected with TM and 22 with SCD), who received allo-HSCT in 6 GETMON units between November 1989 and December 2014. Event-free survival three years post-transplant was 81% and overall survival 92% in patients with TM. Event-free survival three years post-transplant was 79% and overall survival 85% in patients with SCD. The results of this series are comparable to the results of other international series and offer a platform from which to continue trying to improve the evolution of these patients. Copyright © 2018 Elsevier España, S.L.U. All rights reserved.

Report this publication

Statistics

Seen <100 times